Molbio Diagnostics Ltd.

Use of Proceeds

Promoters

Book Running Lead Managers

Promoter Shareholding

About the Company

We are an innovative point-of-care (“POC”) diagnostics company focused on expanding access to accurate, rapidand cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. We havedeveloped our ‘Truenat’ platform, which is a novel POC polymerase chain reaction (“PCR”) platform that canoperate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour.As of March 31, 2025, Truenat is patented in more than 100 countries for the diagnosis of multiple infectious andnon-communicable diseases. As of March 31, 2025, we offer molecular testing for 30 diseases, includingtuberculosis (“TB”), COVID, Hepatitis B and C, Human immunodeficiency virus (“HIV”), and HumanPapillomavirus (“HPV”) with 42 assays. We operate in an oligopolistic market with high entry barriers, evidencedby the fact that our platform underwent 13 years of R&D to obtain Indian Council of Medical Research (“ICMR”)certification and our ‘Truenat’ test chip for diagnosing TB is the only one by an Indian company and one of theonly two rapid molecular tests in the world, which has been endorsed by the World Health Organization (“WHO”)for initial diagnosis of TB and rifampicin resistance detection using molecular diagnostic technology. (Source:1Lattice Report). We also provide devices, enabling radiology, digital pathology and breast health screening,through our Subsidiary, Prognosys, Associate, OptraScan and collaboration partner - UE Lifesciences. Further, weare focussed towards building a pipeline of additional products and platforms that are currently at various stagesof development.